Bayer cleared of 'outrageous' breaches in Xarelto ads; Novartis neighbors worry about site demo plans;

@FiercePharma: Bond market pants for Pfizer vet unit's debut offering: Zoetis sets up $3.65B in debt amid final prep for IPO. More | Follow @FiercePharma

 @AlisonBFierce: FierceVaccines brings you the major FDA vaccine approvals from 2012. Special Report | Follow @AlisonBFierce

> Bayer was cleared of alleged "outrageous" breaches of the U.K. pharma industry's marketing code after officials determined that the suspect ad wasn't misleading. Report

> Neighbors to Novartis' ($NVS) site in West Sussex, England, have complained that the company has not discussed its plans to demolish some buildings, possibly to open land for sale and development. Report

> Japan's Teijin Pharma is preparing to launch Ipsen's Somatuline injection, a treatment for acromegaly and pituitary gigantism, in its home country. Report

> Bosnia's top generics maker, Bosnalijek, predicts a 15% increase in profits for 2013, on top of an 11% increase last year. Report

> The liver cancer market is expected to approach $650 million by 2018, with Bayer's Nexavar continuing to dominate the category, GBI Research found. Report

> The Institute of Medicine concluded that the traditional schedule of childhood vaccines doesn't cause health problems in children as feared. Report (sub. req.)

> A new U.S. drugmaker, Vestiq Pharmaceuticals, has launched with two marketed products bought in from other companies. Report

Biotech News

 @FierceBiotech: Popular yesterday: Buzz: $AZN reorg inspires fresh rumors of $SHPG bid. Report | Follow @FierceBiotech

@JohnCFierce: Columnist gushes over Inovio's Kim, a tireless promoter whose stock is trading at .67 and whose flu vax is in PhI. Column | Follow @JohnCFierce

@RyanMFierce: $EXEL's plethora of partnerships bearing fruit as Genentech moves melanoma drug from EXEL into PhIII. More | Follow @RyanMFierce

> FDA green-lights a flu vaccine made with new technology. Story

> Genentech launches PhIII for melanoma combo with GSK in hot pursuit. Article

> AstraZeneca shakeup pushes research chief to top of restructured MedImmune. News

Medical Device News

 @FierceMedDev: FDA plans to clamp down on all-metal hips. Article | Follow @FierceMedDev

 @DamianFierce: Big M&A morning: Stryker's ($SYK) spending $764 million on Chinese orthopedics company Trauson. Release | Follow @DamianFierce

> Stryker to buy Chinese orthopedics biz for $764M. Story

> InfraScan gains FDA backing for next-gen brain hematoma detector. Item

> Analysts: St. Jude at risk for Durata recall. Report

Vaccines News

> IOM confirms safety of childhood vaccine schedule. Report

> CDC: Flu hits epidemic level in U.S. Item

> Protein Sciences nabs Flublok approval. News

> Vaccine stakes upped as dengue dubbed fastest-spreading tropical disease. Article

> Flu vaccine, Tamiflu shortage as influenza sweeps U.S. Story

Pharma Manufacturing News

 @EricPFierce: Amgen to build $200 million monoclonal antibody plant in Singapore. Novartis building there too. More | Follow @EricPFierce

> Wisconsin report adds to drug take-back funding debate. Item

> China ups bounty for tips on counterfeiters to $48,500. Report

> Japan's Mitsui ups stake in India API maker Arch. Story

> FDA spells out user fees for generic drugs. Article

> J&J consent decree cost felt at the pharmacy. More

And Finally... The flu vaccine is not linked to fetal death, a new study found. Report

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.